CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma lines
The bromodomain inhibitor CPI203 induced relatively consistent effects on gene expression and growth across a variety of glioblastoma lines, specifically down-regulating genes associated with DNA replication. We propose that clinically effective BET inhibitors have the potential to induce consistent beneficial effects across a spectrum of glioblastomas.
Authors
- Catherine A. Behrmann (ORCID: https://orcid.org/0000-0003-0704-0884)
- Daniel Woo (ORCID: https://orcid.org/0000-0002-2466-7155)
- Mario Medvedovic
- Mark Hoeprich
- Merissa Pemberton
- Robert M. Lober (ORCID: https://orcid.org/0000-0002-0824-0274)
- Troy Carnwath (ORCID: https://orcid.org/0000-0003-2703-9047)
- Farah Barakat (ORCID: https://orcid.org/0009-0003-3072-3760)
- Eric O’Brien (ORCID: https://orcid.org/0000-0003-3585-7015)
- David R. Plas (ORCID: https://orcid.org/0000-0001-7568-1400)
- Matthew C. Garrett (ORCID: https://orcid.org/0000-0003-4567-7907)
- John Peter Perentesis (ORCID: https://orcid.org/0000-0002-4237-8226)
- Brett VanCauwenbergh
- Yonghua Zhuang (ORCID: https://orcid.org/0000-0002-1822-2395)
- Hailey Spry
- Rebecca Albano
- Anthony J. Paravati
- Rani Nasser
- Marilyn Reed
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Alfaisal University (SA)
- Kettering College (US)
- Kettering Medical Center (US)
- Dayton Children's Hospital (US)
- University of Colorado Cancer Center (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Cincinnati (US)
- University of Cincinnati Medical Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1371/journal.pone.0306846
- Citations
- 1
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Neurosurgery Research and Education Foundation
- College of Medicine, University of Cincinnati
- National Cancer Institute